• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Bristol-Myers Squibb taps Taris’ drug-release tech for bladder cancer trial

December 20, 2017 By Sarah Faulkner

Taris BiomedicalBristol-Myers Squibb (NYSE:BMY) and Taris Biomedical have inked a deal to combine Taris’ investigational GemRIS drug-releasing tech with the pharma company’s PD-1 immune checkpoint inhibitor, Opdivo, in a Phase Ib muscle invasive bladder cancer trial.

As part of the collaboration, Bristol-Myers has also made an equity investment in Lexington, Mass.-based Taris.

Taris’ GemRIS system is designed to release drugs continuously in the bladder over the course of several weeks, even months. The device is deployed and retrieved using minimally-invasive procedures that can be done in-office.

“This is the first study evaluating the potential benefits of combining TAR-200 with a systemically administered immune checkpoint inhibitor,” Taris’ president & CEO Purnanand Sarma said in prepared remarks. “MIBC is a potentially lethal disease with high unmet clinical need. We are excited to partner with Bristol-Myers Squibb, a world-leader in oncology, to advance approaches that may provide meaningful benefit to patients.”

“We continue to explore multiple approaches to treating cancer as part of our broad research program focused on delivering the next wave of oncology therapies,” Dr. Fouad Namouni, head of development for Bristol-Myers’ oncology business, added. “Partnering with Taris will allow us to advance our scientific understanding of combining Opdivo with continuous local chemotherapy as we seek to improve outcomes for patients with this aggressive form of bladder cancer.”

Want to stay on top of DDBN content? Sign up for our e-mail newsletter for a weekly dose of drug-device news.

Filed Under: Clinical Trials, Featured, Oncology, Pharmaceuticals, Wall Street Beat Tagged With: Bristol-Myers Squibb Co., Taris Biomedical

IN CASE YOU MISSED IT

  • Medtronic to invest $50M in India Diabetes center
  • Flat Medical partners with Mercury Medical on smart syringe distribution
  • Glucotrack to effect a reverse stock split
  • Medtronic unveils ‘MiniMed’ as name for soon-to-be separated Diabetes unit
  • Insulet, Marvel collab to unveil comic book hero with type 1 diabetes

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS